TRAIL-induced apoptosis: between tumor therapy and immunopathology

Corazza, Nadia; Kassahn, Daniela; Jakob, Sabine; Badmann, Anastasia; Brunner, Thomas (2009). TRAIL-induced apoptosis: between tumor therapy and immunopathology. Annals of the New York Academy of Sciences, 1171, pp. 50-58. Boston, Mass.: Blackwell 10.1111/j.1749-6632.2009.04905.x

Full text not available from this repository.

The death ligand members of the tumor necrosis factor (TNF) family are potent inducers of apoptosis in a variety of cell types. In particular, TNF-related apoptosis-inducing ligand (TRAIL) has recently received much scientific and commercial attention because of its potent tumor cell-killing activity while leaving normal untransformed cells mostly unaffected. Furthermore, TRAIL strongly synergizes with conventional chemotherapeutic drugs in inducing tumor cell apoptosis, making it a most promising candidate for future cancer therapy. Increasing evidence indicates, however, that TRAIL may also induce or modulate apoptosis in primary cells. A particular concern is the potential side effect of TRAIL-based tumor therapies in the liver. In this review we summarize some of the recent findings on the role of TRAIL in tumor cell and hepatocyte apoptosis.

Item Type:	Journal Article (Further Contribution)
Division/Institute:	04 Faculty of Medicine > Service Sector > Institute of Pathology
UniBE Contributor:	Corazza, Nadia, Kassahn, Daniela, Badmann, Anastasia, Brunner, Thomas (A)
ISSN:	0077-8923
ISBN:	19723037
Publisher:	Blackwell
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 15:08
Last Modified:	29 Mar 2023 23:33
Publisher DOI:	10.1111/j.1749-6632.2009.04905.x
PubMed ID:	19723037
Web of Science ID:	000269657300007
URI:	https://boris.unibe.ch/id/eprint/29967 (FactScience: 165537)